- Previous Close
25.84 - Open
26.09 - Bid 27.13 x 300
- Ask 27.24 x 300
- Day's Range
26.09 - 27.30 - 52 Week Range
20.84 - 49.50 - Volume
631,990 - Avg. Volume
973,440 - Market Cap (intraday)
2.252B - Beta (5Y Monthly) 1.86
- PE Ratio (TTM)
-- - EPS (TTM)
-1.58 - Earnings Date Feb 25, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.20
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
beamtx.com472
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: BEAM
View More
Performance Overview: BEAM
Trailing total returns as of 2024-11-27, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BEAM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BEAM
View MoreValuation Measures
Market Cap
2.14B
Enterprise Value
1.38B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.05
Price/Book (mrq)
2.70
Enterprise Value/Revenue
3.94
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.07%
Return on Assets (ttm)
-9.27%
Return on Equity (ttm)
-18.29%
Revenue (ttm)
349.64M
Net Income Avi to Common (ttm)
-143.59M
Diluted EPS (ttm)
-1.58
Balance Sheet and Cash Flow
Total Cash (mrq)
925.76M
Total Debt/Equity (mrq)
20.48%
Levered Free Cash Flow (ttm)
-38.55M